U.S. Markets closed

Sucampo Pharmaceuticals, Inc. (SCMP)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
11.70-0.45 (-3.70%)
At close: 4:00PM EDT

11.70 0.00 (0.00%)
After hours: 4:35PM EDT

People also watch
SUPNAMAGHZNPDEPOFOLD
Full screen
Previous Close12.15
Open12.20
Bid8.15 x 100
Ask14.30 x 100
Day's Range11.55 - 12.20
52 Week Range9.30 - 17.55
Volume752,873
Avg. Volume489,817
Market Cap542M
Beta0.80
PE Ratio (TTM)-3.35
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube7 days ago

    ETFs with exposure to Sucampo Pharmaceuticals, Inc. : September 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sucampo Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SCMP-US. Comparing the performance and risk of Sucampo Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
    Capital Cube9 days ago

    Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017

    Categories: Yahoo FinanceGet free summary analysis Sucampo Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Sucampo Pharmaceuticals, Inc. – Nektar Therapeutics, Progenics Pharmaceuticals, Inc., Pfizer Inc., Akorn, Inc., Ironwood Pharmaceuticals, Inc. Class A, Synergy Pharmaceuticals, Inc., Abbott Laboratories and Evoke Pharma, Inc. (NKTR-US, ... Read more (Read more...)

  • Sucampo (SCMP) Up 17.1% Since Earnings Report: Can It Continue?
    Zacks13 days ago

    Sucampo (SCMP) Up 17.1% Since Earnings Report: Can It Continue?

    Sucampo (SCMP) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.